Practical Neurology

12/13/2025

New clinical practice guidelines for the diagnosis and management of functional have been published in the Neurology Journal by the American Academy of Neurology (AAN) endorsed by the American Epilepsy Society.

The American Academy of Neurology (AAN) has published new clinical practice guidelines in Neurology, providing evidence-based recommendations for the diag…

12/12/2025

The U.S. Food and Drug Administration has approved ( ; Amgen) for the treatment of people with AChR+ or MuSK+ generalized .
https://ow.ly/rKma50XIJ5i
Myasthenia Gravis Foundation of America, Inc. American Association of Neuromuscular & Electrodiagnostic Medicine - AANEM American Academy of Neurology (AAN)

The Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon; Amgen, Thousand Oaks, CA) for the treatment of generalized myasthenia grav…

12/11/2025

Behavioral and psychiatric comorbidities are common in ; Dr. Waldron (David Geffen School of Medicine at UCLA) reviews evidence-based options, from SSRIs and antipsychotics, to medications and ASMs that support mood and behavior. https://ow.ly/FV0c50XHaZn
American Epilepsy Society UCLA Health Child Neurology Society American Psychiatric Association

Treatment of behavioral/psychiatric comorbidities requires consideration of underlying causes, symptom profile, antiseizure medications, and epilepsy type

12/10/2025

DEE-SWAS remains difficult to treat, with heterogeneous presentations, variable responses, and urgent need for standardized approaches to therapy and outcome measurement. In a new review article, Drs. Rao, Stowe, Kelley, Pavuluri, Liu, & Patel examine current challenges and paths forward.
https://ow.ly/ahfO50XGGgk
UCLA Health Boston Children’s Hospital Johns Hopkins Medicine Children's Nebraska CHOC Duke University School of Medicine American Epilepsy Society American Academy of Neurology (AAN)

12/10/2025

New adapted clinical practice for the outpatient management of have been published in Annals of Family Medicine.
https://ow.ly/iKY050XGG6u
Brain Injury Association of America American Academy of Neurology (AAN) International Brain Injury Association American College of Physicians (ACP)

New adapted clinical practice guidelines for the outpatient management of traumatic brain injury (TBI) have been published in Annals of Family Medicine. D…

12/08/2025

The U.S. Food and Drug Administration has granted Fast Track Designation to capsules for the treatment of people with generalized .
https://ow.ly/Sy3550XG1NJ
Myasthenia Gravis Foundation of America, Inc. American Association of Neuromuscular & Electrodiagnostic Medicine - AANEM American Academy of Neurology (AAN)

The Food and Drug Administration (FDA) has granted Fast Track Designation to cladribine capsules (EMD Serono, Boston, MA) for the treatment of individuals…

12/07/2025

Minimally invasive surgery within 72 hrs did not significantly improve 6-month disability or reduce 30-day mortality vs medical management alone in patients with supratentorial . Data published in JAMA Neurology. https://ow.ly/vwhY50XFotR
Endovascular Today American Heart Association

According to results from the MIND clinical trial (NCT03342664) published in JAMA Neurology, minimally invasive surgery within 72 hours using the Artemis …

12/05/2025

New findings from ancillary US studies show structured lifestyle interventions linked to apnea, health, and resilience in older adults at risk for ’s— https://ow.ly/AyF250XCsbo
CTAD Conference Alzheimer's Association American Academy of Neurology (AAN)

New findings from 3 ancillary studies to the US POINTER trial (NCT03688126)—presented at the 18th annual Clinical Trials in Alzheimer’s Disease (CTAD) con…

12/04/2025

The diagnostic accuracy of 's plasma assay for 's pathology was assessed in a real-world cohort in a study presented at .
https://ow.ly/2MaP50XC6RG
U.S. Food and Drug Administration CTAD Conference American Academy of Neurology (AAN) Alzheimer's Association

A study presented at the 18th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference evaluated the Food and Drug Administration (FDA)-cleared and…

12/04/2025

Treatment with the anti- antibody in people with dominantly inherited disease was associated with substantial reductions in the novel eMTBR-tau243, indicating strong target engagement. https://ow.ly/HIi950XBIfI
CTAD Conference American Academy of Neurology (AAN) Alzheimer's Association Eisai Global

Treatment with the investigational anti-tau antibody etalanetug (E2814; Eisai, Tokyo, Japan) for individuals with dominantly inherited Alzheimer disease (…

12/03/2025

LM11A-31, a p75 neurotrophin receptor modulator, reduced p- and preserved visuospatial function in disease, with proteomic changes linked to synaptic biology. Data presented at .
https://ow.ly/BKX450XBBz0
CTAD Conference Alzheimer's Association American Academy of Neurology (AAN)

Modulation of the p75 neurotrophin receptor using LM11A-31 (PharmatrophiX, Menlo Park, CA), an investigational small molecule agent, may slow disease-rela…

12/03/2025

At , Takeshi Iwatsubo, MD, PhD was honored as the recipient of this year’s Lifetime Achievement Award in ’s Disease Therapeutic Research. https://ow.ly/ERu250XAYKh
CTAD Conference Alzheimer's Association National Center of Neurology and Psychiatry - 国立精神・神経医療研究センター

Takeshi Iwatsubo, MD, PhD was recognized at the 18th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference as the recipient of this year’s Lifet…